Skip to main content
. 2021 Sep 10;34(2):219–225. doi: 10.4103/tcmj.tcmj_84_21

Table 2.

Overall survival rates of patients initially treated with transarterial chemoembolization plus sorafenib (n=56) and transarterial chemoembolization alone (n=112)

Overall survival rates TACE plus Sorafenib, n (%) TACE alone, n (%) P
1-year 38 (67.9) 13 (11.6) <0.001
2-year 21 (37.5) 5 (4.5) <0.001
3-year 16 (28.6) 2 (1.8) <0.001
5-year 6 (10.7) 1 (0.9) <0.001

TACE: Transarterial chemoembolization